azacitidine and quinazolines

azacitidine has been researched along with quinazolines in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (6.25)	29.6817
2010's	13 (81.25)	24.3611
2020's	2 (12.50)	2.80

Authors

Authors	Studies
Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM	1
Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C	1
Berkova, Z; Koblas, T; Leontovyč, I; Pektorova, L; Saudek, F; Zacharovova, K	1
Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F	1
Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A	1
Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ	1
Fiszbein, A; Kornblihtt, AR; Petrillo, E; Schor, IE	1
Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D	1
Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ	1
Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E	1
Erba, HP	1
Gao, B; Li, GH; Shao, GG; Yang, B; Yang, ZG	1
Barat, C; Dental, C; Ouellet, M; Proust, A; Tremblay, MJ	1
Beizer, A; Belitsky, G; Bugaeva, P; Fedorov, D; Katz, R; Kirsanov, K; Lesovaya, E; Lizogub, O; Maksimova, V; Shalginskikh, N; Usalka, O; Vlasova, O; Yakubovskaya, M	1
Gu, X; Li, B; Li, H; Li, M; Sun, X; Xu, P; Zhu, Y; Zuo, Q	1

Reviews

1 review(s) available for azacitidine and quinazolines

Article	Year
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leukemia research, 2015, Volume: 39, Issue:2 Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones	2015

Article

Year

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.

Leukemia research, 2015, Volume: 39, Issue:2

Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones

2015

Trials

3 trial(s) available for azacitidine and quinazolines

Article	Year
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome	2012
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure	2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia research, 2014, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction	2014

Other Studies

12 other study(ies) available for azacitidine and quinazolines

Article	Year
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer biology & therapy, 2006, Volume: 5, Issue:11 Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction	2006
The effect of epigenetic factors on differentiation of pancreatic progenitor cells into insulin-producing cells. Transplantation proceedings, 2011, Volume: 43, Issue:9 Topics: Azacitidine; Azepines; C-Peptide; Cell Culture Techniques; Cell Differentiation; Decitabine; Epigenesis, Genetic; Humans; Hydroxamic Acids; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Keratin-19; Models, Biological; Models, Genetic; Pancreas; Pyrroles; Quinazolines; Stem Cells; Transcription Factors	2011
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PloS one, 2012, Volume: 7, Issue:7 Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins	2012
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene, 2013, Sep-12, Volume: 32, Issue:37 Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines	2013
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncology reports, 2013, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines	2013
Intragenic epigenetic changes modulate NCAM alternative splicing in neuronal differentiation. The EMBO journal, 2013, Aug-14, Volume: 32, Issue:16 Topics: Alternative Splicing; Animals; Azacitidine; Azepines; Cell Differentiation; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; DNA Methylation; DNA Primers; Epigenesis, Genetic; Exons; Mice; Neural Cell Adhesion Molecules; Neurons; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sequence Analysis, DNA	2013
News products to avoid. Prescrire international, 2014, Volume: 23, Issue:148 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur	2014
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PloS one, 2014, Volume: 9, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases	2014
5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:10 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinazolines	2015
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration. Journal of immunology (Baltimore, Md. : 1950), 2017, 02-01, Volume: 198, Issue:3 Topics: Acetamides; Azacitidine; Azepines; Blood-Brain Barrier; Bryostatins; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Cells, Cultured; Chemokine CCL2; Cytokines; Decitabine; HIV-1; Humans; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Phorbol Esters; Quinazolines; Receptors, Cell Surface; Virus Latency	2017
HeLa TI cell-based assay as a new approach to screen for chemicals able to reactivate the expression of epigenetically silenced genes. PloS one, 2021, Volume: 16, Issue:6 Topics: Azacitidine; Azepines; DNA Methylation; Epigenesis, Genetic; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Phthalimides; Quinazolines; Tryptophan	2021
H3K9me2 regulates early transcription factors to promote mesenchymal stem‑cell differentiation into cardiomyocytes. Molecular medicine reports, 2021, Volume: 24, Issue:2 Topics: Animals; Azacitidine; Azepines; Cell Differentiation; Female; GATA4 Transcription Factor; Gene Knockdown Techniques; Histone Demethylases; Histone-Lysine N-Methyltransferase; Histones; Homeobox Protein Nkx-2.5; Male; MEF2 Transcription Factors; Mesenchymal Stem Cells; Myocytes, Cardiac; Primary Cell Culture; Quinazolines; Rats, Wistar; Transcription Factors; Troponin T	2021